Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MedChew RL
- Development stage
- Preclinical
- Lead developer
- Axim Biotechnologies
- Modality
- Small Molecules
- Administration
- Oral, Oral Mucosal
01
Overview
MedChew RL is a medicated chewing gum under development by AXIM Biotechnologies, intended for the treatment of restless leg syndrome (RLS). It appears to be part of a larger portfolio of cannabinoid-based chewing gums developed by the company for various neurological and pain indications. The drug is designed for oral mucosal absorption, potentially offering advantages such as extended dosing and avoidance of first-pass metabolism compared to conventional oral or spray formulations.
- Brand names
- MedChew RL
- Other names
- CanChew® RL
02
Targets
CNR1 (Cannabinoid receptor 1)
Beyond the preview
Go deeper on MedChew RL.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MedChew RL.